Insider Selling: Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells 33,668 Shares of Stock

Key Points

• Vor Biopharma major shareholder Reprogrammed Interchange LLC sold 33,668 shares at an average price of $30.32, totaling over $1 million, while reducing their ownership by 2.57% to approximately 1.28 million shares.
• Following the insider selling, Vor Biopharma stock fell by 1.9%, closing at $30.22 with a market capitalization of $207.01 million.
• Analysts have varying ratings on the stock, with some upgrades giving price targets as high as $64.00, while others have issued a "strong sell" rating.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 33,668 shares of the stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $30.32, for a total value of $1,020,813.76. Following the sale, the insider owned 1,278,118 shares in the company, valued at approximately $38,752,537.76. This represents a 2.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The stock was sold at an average price of $32.44, for a total value of $713,874.64.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The stock was sold at an average price of $30.97, for a total value of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total transaction of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total transaction of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The stock was sold at an average price of $37.01, for a total transaction of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.

Vor Biopharma Stock Down 1.9%

NASDAQ VOR traded down $0.59 on Wednesday, hitting $30.22. The stock had a trading volume of 724,134 shares, compared to its average volume of 393,854. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80. The company has a market capitalization of $207.01 million, a P/E ratio of -0.11 and a beta of 2.07. The business has a 50-day moving average of $37.28.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Stifel Nicolaus upgraded shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective on the stock in a research report on Wednesday, September 24th. Robert W. Baird upgraded shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $20.00 to $64.00 in a research report on Wednesday. Zacks Research cut shares of Vor Biopharma from a "hold" rating to a "strong sell" rating in a research report on Monday. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Finally, Wall Street Zen downgraded shares of Vor Biopharma to a "strong sell" rating in a research note on Saturday, June 28th. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $77.83.

Institutional Trading of Vor Biopharma

Large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in Vor Biopharma during the 2nd quarter valued at approximately $66,000. Money Concepts Capital Corp boosted its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma during the 1st quarter valued at approximately $100,000. Finally, Jane Street Group LLC bought a new stake in Vor Biopharma during the 1st quarter valued at approximately $140,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.